Zetia vs Leqvio: Head-to-Head Efficacy Comparison

How These Two Drugs Lower LDL-C Through Different Pathways

Ezetimibe and inclisiran reduce LDL cholesterol through mechanisms that share no overlap. Understanding why matters for deciding which fits a given patient profile.

Ezetimibe blocks the Niemann-Pick C1-Like 1 (NPC1L1) transporter on the brush border of the small intestine, reducing dietary and biliary cholesterol absorption by about 54% [1]. The liver compensates by upregulating LDL receptors, pulling more LDL-C from the bloodstream. This compensatory mechanism is the same reason statins work: both increase hepatic LDL receptor expression, though through different triggers. When combined with a statin, the dual mechanism produces additive LDL-C lowering of roughly 23-24% beyond the statin alone [2].

Inclisiran takes a completely different approach. It is a synthetic small interfering RNA (siRNA) conjugated to N-acetylgalactosamine (GalNAc), which directs the molecule to hepatocytes [3]. Once inside the liver cell, inclisiran silences messenger RNA encoding PCSK9 protein. Less PCSK9 means fewer LDL receptors are tagged for degradation, so more receptors survive to clear LDL-C from circulation. The effect persists for roughly six months per dose because the siRNA remains active within the RNA-induced silencing complex (RISC).

One key distinction: ezetimibe acts in the gut lumen, inclisiran acts inside liver cells. That difference shapes their drug interaction profiles, adverse event patterns, and suitability for patients with hepatic versus gastrointestinal concerns.

LDL-C Lowering: Quantifying the Gap Between Zetia and Leqvio

Inclisiran produces roughly double the LDL-C percentage reduction that ezetimibe achieves on top of statin therapy. The numbers are consistent across multiple trials.

In the pooled analysis of ORION-10 (N=1,561) and ORION-11 (N=1,617), inclisiran 284 mg administered subcutaneously on day 1, day 90, and every 6 months thereafter reduced LDL-C by 52.3% (time-averaged) and 50.7% (at day 510) versus placebo, with both populations already on maximally tolerated statin therapy [3]. The between-group difference at day 510 reached 50.7 percentage points (95% CI: 47.0 to 54.3, P<0.001) in ORION-10 [3].

For ezetimibe, the IMPROVE-IT trial (N=18,144) demonstrated a mean LDL-C reduction of 24% when 10 mg ezetimibe was added to simvastatin 40 mg, bringing the median LDL-C from 69.5 mg/dL (simvastatin alone) to 53.7 mg/dL (combination) at one year [2]. The absolute LDL-C difference between arms was approximately 16 mg/dL sustained over a median 6-year follow-up.

A practical framing: if a patient on atorvastatin 40 mg has a residual LDL-C of 100 mg/dL, adding ezetimibe would be expected to lower LDL-C to roughly 76-77 mg/dL. Adding inclisiran instead would be expected to bring it to approximately 48-50 mg/dL. That difference matters most for patients who need to reach aggressive targets below 55 mg/dL, such as those with established atherosclerotic cardiovascular disease (ASCVD) per the 2018 AHA/ACC cholesterol guideline [4].

The 2022 ACC Expert Consensus Decision Pathway states: "For patients with clinical ASCVD not at LDL-C goal on maximally tolerated statin therapy, addition of ezetimibe is recommended as the first intensification step, followed by a PCSK9 inhibitor if the target is still not achieved" [5]. Inclisiran now occupies a position alongside monoclonal antibody PCSK9 inhibitors in that second-line tier.

Cardiovascular Outcomes: What the Trials Actually Show

Ezetimibe has proven outcomes data. Inclisiran does not yet. This is the single most important distinction between the two drugs for evidence-based prescribing.

IMPROVE-IT randomized 18,144 patients who had been hospitalized for acute coronary syndrome within the preceding 10 days to simvastatin 40 mg plus either ezetimibe 10 mg or placebo [2]. Over a median follow-up of 6 years, the primary composite endpoint (cardiovascular death, major coronary event, or nonfatal stroke) occurred in 32.7% of the ezetimibe-statin group versus 34.7% of the statin-monotherapy group (HR 0.936; 95% CI: 0.89 to 0.99; P=0.016) [2]. That 6.4% relative risk reduction translated to a 2.0 percentage-point absolute risk reduction and a number needed to treat of 50 over 7 years.

Dr. Christopher Cannon, lead investigator of IMPROVE-IT at Brigham and Women's Hospital, noted: "This is the first trial to show that adding a non-statin drug to a statin to further reduce LDL cholesterol does reduce cardiovascular events" [2].

For inclisiran, the ORION-10 and ORION-11 trials were designed as LDL-C lowering studies, not cardiovascular outcomes trials. Adjudicated MACE was a prespecified exploratory endpoint. In ORION-11, cardiovascular events occurred in 7.4% of the inclisiran group versus 10.2% of placebo (HR 0.74; 95% CI: 0.58 to 0.94), but the trial was neither powered nor designed to draw definitive conclusions from this [3].

The dedicated cardiovascular outcomes trial, ORION-4 (NCT03705234), enrolled over 15,000 adults with ASCVD and is expected to report results in 2026 [6]. Until those results are available, prescribers rely on the well-established relationship between LDL-C lowering and cardiovascular risk reduction documented in CTT Collaboration meta-analyses: each 1 mmol/L (38.7 mg/dL) reduction in LDL-C lowers major vascular events by approximately 22% [7].

Dr. Kausik Ray, primary investigator of ORION-11 at Imperial College London, stated regarding inclisiran's LDL-lowering magnitude: "A 50% reduction in LDL cholesterol sustained over time would be expected to yield significant cardiovascular benefit based on the totality of evidence linking LDL to atherosclerotic events" [3].

Safety and Tolerability: Two Very Different Profiles

Both drugs are generally well tolerated, but their adverse event signatures differ meaningfully because of their distinct routes of administration and mechanisms.

Ezetimibe's safety record spans over two decades of clinical use. In IMPROVE-IT, rates of myopathy, rhabdomyolysis, gallbladder-related adverse events, hepatitis, and cancer did not differ significantly between ezetimibe-statin and statin-alone groups over 6 years of follow-up [2]. The most commonly reported side effects in labeling include upper respiratory tract infection, diarrhea, arthralgia, and sinusitis, each occurring at rates within 1-2% of placebo [8]. Ezetimibe is contraindicated with a statin in active liver disease or unexplained persistent transaminase elevation.

Inclisiran's safety data come from a shorter observation window. Across ORION-10 and ORION-11, the most notable adverse event was injection-site reaction, occurring in 5% of inclisiran patients versus 0.7% of placebo patients [3]. These reactions were predominantly mild (erythema, pain, or rash) and did not lead to treatment discontinuation in most cases. Serious adverse events, hepatic events, and new-onset diabetes occurred at comparable rates between inclisiran and placebo groups through 18 months [3]. The FDA label for Leqvio notes that injection-site reactions are the primary safety signal, with no identified hepatotoxicity concern [9].

One practical consideration: ezetimibe requires daily pill adherence. Inclisiran is administered by a healthcare professional every 6 months after the loading phase. For patients who struggle with daily medication compliance, the twice-yearly injection schedule of inclisiran may offer a real-world adherence advantage that does not show up in clinical trial efficacy numbers.

Cost and Access: The Practical Reality

The cost difference between generic ezetimibe and branded inclisiran is substantial and shapes real-world prescribing patterns, especially for patients without strong insurance coverage.

Generic ezetimibe 10 mg tablets are available at most pharmacies for $10-15 per month, sometimes less with discount programs [10]. It is on virtually every commercial and Medicare Part D formulary without prior authorization. The FDA approved generic ezetimibe in December 2016, and competition among manufacturers has driven prices down steadily.

Leqvio (inclisiran) carries a wholesale acquisition cost of approximately $3,250 per injection, or roughly $6,500 per year after the three-injection first year [9]. Access requires prior authorization from most insurers, typically with documented failure or intolerance of ezetimibe and high-intensity statin therapy. Medicare Part B covers Leqvio because it is administered by a healthcare professional in an office or clinic setting, which removes the Part D coverage gap issue but still involves cost-sharing [11].

The 2022 Institute for Clinical and Economic Review (ICER) assessment estimated that inclisiran would need a net price of approximately $3,600-$5,000 per year to align with commonly cited cost-effectiveness thresholds of $100,000-$150,000 per quality-adjusted life year (QALY) gained, assuming cardiovascular outcomes benefit similar to that predicted by LDL-C lowering [12]. Formulary coverage continues to expand, but ezetimibe's cost advantage remains overwhelming for patients who can reach their LDL-C target with statin-plus-ezetimibe.

When to Choose One Over the Other: A Clinical Decision Framework

The choice between ezetimibe and inclisiran is rarely binary. Guidelines position them sequentially, not as direct alternatives.

The 2018 AHA/ACC Multisociety Guideline on Management of Blood Cholesterol recommends ezetimibe as the first add-on to maximally tolerated statin therapy for patients with clinical ASCVD who have not reached their LDL-C goal [4]. If LDL-C remains at or above 70 mg/dL (or the patient does not achieve a 50% or greater reduction), a PCSK9-targeted agent is the next consideration. Inclisiran fits into that second tier alongside evolocumab and alirocumab.

Specific clinical scenarios favor one drug:

Ezetimibe is typically preferred when: The patient needs moderate additional LDL-C lowering (15-25% beyond statin), cost is a constraint, the patient has no issue with daily oral medication, and the LDL-C target can be achieved with ezetimibe addition. Also appropriate as a statin alternative in statin-intolerant patients who still have relatively modest LDL-C elevation.

Inclisiran may be preferred when: The patient has ASCVD with LDL-C persistently above goal despite statin plus ezetimibe, the patient requires large additional LDL-C reduction (40-50%+), adherence to daily oral medications is poor, or the patient prefers twice-yearly injections over daily pills. Also relevant for patients with heterozygous familial hypercholesterolemia (HeFH) who need aggressive LDL-C lowering beyond what oral agents achieve [13].

Using both together: Ezetimibe and inclisiran can be prescribed concurrently. Because they work through independent mechanisms (cholesterol absorption inhibition and PCSK9 silencing), their LDL-C lowering effects are expected to be additive. A patient on high-intensity statin, ezetimibe, and inclisiran could theoretically achieve LDL-C reductions exceeding 75-80% from untreated baseline, which is relevant for patients with familial hypercholesterolemia or very high-risk ASCVD.

Statin Intolerance: How Each Drug Performs as Monotherapy

For patients who cannot tolerate any statin, ezetimibe and inclisiran each have data supporting standalone use, though the evidence base differs in depth.

Ezetimibe monotherapy (without a statin) reduces LDL-C by approximately 18% [8]. That is modest compared to even moderate-intensity statin therapy, but it provides a well-tolerated oral option. The EZETIMIBE Lipid-Lowering Trial on Prevention of Atherosclerosis in 75 or Older (EWTOPIA 75, N=3,796) showed that ezetimibe monotherapy reduced the composite cardiovascular endpoint by 34% in elderly Japanese patients without prior coronary disease (HR 0.66; 95% CI: 0.50 to 0.86; P=0.002) [14].

Inclisiran as monotherapy (in statin-intolerant populations) was evaluated in ORION-8, the open-label extension study that included statin-intolerant patients. LDL-C reductions of approximately 44-48% were maintained over extended follow-up regardless of background statin use [15]. For patients who are completely statin-intolerant, inclisiran offers a much larger absolute LDL-C reduction than ezetimibe monotherapy.

The practical sequence for statin-intolerant patients recommended by the National Lipid Association is: attempt statin rechallenge at reduced dose or alternate-day dosing, then add ezetimibe, then consider PCSK9-targeted therapy if LDL-C remains above goal [16].

What ORION-4 Will Change

The biggest missing piece in the inclisiran evidence base is a dedicated, adequately powered cardiovascular outcomes trial. ORION-4 aims to fill that gap.

ORION-4 (NCT03705234) is a randomized, double-blind, placebo-controlled trial enrolling approximately 15,000 patients aged 55 and older with pre-existing ASCVD across the United Kingdom and the United States [6]. The primary endpoint is time to first major adverse cardiovascular event (MACE: coronary heart disease death, myocardial infarction, ischemic stroke, or urgent coronary revascularization). The trial is conducted by the Clinical Trial Service Unit at the University of Oxford, with results anticipated in 2026.

If ORION-4 confirms a cardiovascular benefit proportional to LDL-C reduction (as CTT meta-analyses would predict), inclisiran's position in treatment algorithms could shift earlier. If the benefit falls short of predictions, questions about non-LDL mechanisms and the difference between PCSK9 silencing versus PCSK9 binding (as with monoclonal antibodies) will intensify. Either result will reshape the practical comparison with ezetimibe. The 2024 ESC/EAS dyslipidaemia guideline update already includes inclisiran as a recommended option for LDL-C lowering in high-risk patients, with the caveat that dedicated outcomes data were pending at the time of publication [17].

Patients currently on inclisiran should continue therapy while awaiting ORION-4 results. For clinicians making new prescribing decisions, the ACC consensus pathway recommends ezetimibe first, with inclisiran reserved for patients not at goal after maximal oral therapy [5].